CEBPZ and acute myeloid leukemia: Moreover, NPM1 mutation was not correlated with better outcome (HR, 1.05; 95%CI, 0.2–5.2; p = .94); conversely, core binding factor (CBF) AML patients displayed a better prognosis (HR, 0.03; 95%CI, 0–87; p = .39; Figure 1B,C).